PL379827A1 - Wykrywanie obniżonej odpowiedzi na chemioterapię z zastosowaniem cytostatyków z grupy taksoidów - Google Patents

Wykrywanie obniżonej odpowiedzi na chemioterapię z zastosowaniem cytostatyków z grupy taksoidów

Info

Publication number
PL379827A1
PL379827A1 PL379827A PL37982706A PL379827A1 PL 379827 A1 PL379827 A1 PL 379827A1 PL 379827 A PL379827 A PL 379827A PL 37982706 A PL37982706 A PL 37982706A PL 379827 A1 PL379827 A1 PL 379827A1
Authority
PL
Poland
Prior art keywords
toxoids
cytostatics
chemotherapy
detection
group
Prior art date
Application number
PL379827A
Other languages
English (en)
Other versions
PL217731B1 (pl
Inventor
Tomasz Byrski
Jacek Gronwald
Jan Lubiński
Tomasz Huzarski
Steven Narod
Original Assignee
Tomasz Byrski
Jacek Gronwald
Jan Lubiński
Tomasz Huzarski
Steven Narod
Pomorska Akademia Medyczna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tomasz Byrski, Jacek Gronwald, Jan Lubiński, Tomasz Huzarski, Steven Narod, Pomorska Akademia Medyczna filed Critical Tomasz Byrski
Priority to PL379827A priority Critical patent/PL217731B1/pl
Priority to US11/809,574 priority patent/US20080241834A1/en
Priority to CA002650448A priority patent/CA2650448A1/en
Priority to RU2008146886/15A priority patent/RU2008146886A/ru
Priority to PCT/PL2007/000035 priority patent/WO2007139411A2/en
Priority to EP07747744.6A priority patent/EP2032720B1/en
Priority to AU2007268378A priority patent/AU2007268378A1/en
Publication of PL379827A1 publication Critical patent/PL379827A1/pl
Priority to ZA200810173A priority patent/ZA200810173B/xx
Publication of PL217731B1 publication Critical patent/PL217731B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL379827A 2006-06-01 2006-06-01 Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi PL217731B1 (pl)

Priority Applications (8)

Application Number Priority Date Filing Date Title
PL379827A PL217731B1 (pl) 2006-06-01 2006-06-01 Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi
US11/809,574 US20080241834A1 (en) 2006-06-01 2007-06-01 Method for improving neoadjuvant chemotherapy
CA002650448A CA2650448A1 (en) 2006-06-01 2007-06-01 Fast assignment of adequate neoadjuvant chemotherapy for breast cancer patients based on the identification of constitutional brca1 mutations
RU2008146886/15A RU2008146886A (ru) 2006-06-01 2007-06-01 Быстрое назначение адекватной неоадъювантной химиотерапии пациентам, страдающим раком молочной железы, основанное на идентификации системных мутаций brca1
PCT/PL2007/000035 WO2007139411A2 (en) 2006-06-01 2007-06-01 Fast assignment of adequate neoadjuvant chemotherapy for breast cancer patients based on the identification of constitutional brca1 mutations
EP07747744.6A EP2032720B1 (en) 2006-06-01 2007-06-01 Fast assignment of adequate neoadjuvant chemotherapy for breast cancer patients based on the identification of constitutional brca1 mutations
AU2007268378A AU2007268378A1 (en) 2006-06-01 2007-06-01 Fast assignment of adequate neoadjuvant chemotherapy for breast cancer patients based on the identification of contitutional BRCA1 mutations
ZA200810173A ZA200810173B (en) 2006-06-01 2008-11-28 Fast assignment of adequate neoadjuvant chemotherapy for breast cancer patients based on the identification of constitutional BRCA1 mutations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL379827A PL217731B1 (pl) 2006-06-01 2006-06-01 Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi

Publications (2)

Publication Number Publication Date
PL379827A1 true PL379827A1 (pl) 2007-12-10
PL217731B1 PL217731B1 (pl) 2014-08-29

Family

ID=38779112

Family Applications (1)

Application Number Title Priority Date Filing Date
PL379827A PL217731B1 (pl) 2006-06-01 2006-06-01 Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi

Country Status (8)

Country Link
US (1) US20080241834A1 (pl)
EP (1) EP2032720B1 (pl)
AU (1) AU2007268378A1 (pl)
CA (1) CA2650448A1 (pl)
PL (1) PL217731B1 (pl)
RU (1) RU2008146886A (pl)
WO (1) WO2007139411A2 (pl)
ZA (1) ZA200810173B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL212012B1 (pl) * 2008-07-06 2012-07-31 Tomasz Byrski Wykrywanie podwyższonej podatności na chemioterapię z zastosowaniem cytostatyków platynowych
US20130029926A1 (en) * 2009-11-05 2013-01-31 Myriad Genetics, Inc. Compositions and methods for determing cancer susceptibility
RU2445373C1 (ru) * 2010-09-15 2012-03-20 Учреждение Российской академии медицинских наук Российский онкологический научный центр им. Н.Н. Блохина РАМН СПОСОБ ОПРЕДЕЛЕНИЯ ГЕНОТИПА ЧЕЛОВЕКА ПО ПОЛИМОРФИЗМУ В ПОЗИЦИИ 4343 ГЕНА BRCA1 (rs1799950)
RU2445372C1 (ru) * 2010-09-15 2012-03-20 Учреждение Российской академии медицинских наук Российский онкологический научный центр им. Н.Н. Блохина РАМН СПОСОБ ОПРЕДЕЛЕНИЯ ГЕНОТИПА ЧЕЛОВЕКА ПО ПОЛИМОРФИЗМУ В ПОЗИЦИИ 6174 ГЕНА BRCA2 (617delT)
RU2445371C1 (ru) * 2010-09-15 2012-03-20 Учреждение Российской академии медицинских наук Российский онкологический научный центр им. Н.Н. Блохина РАМН СПОСОБ ОПРЕДЕЛЕНИЯ ГЕНОТИПА ЧЕЛОВЕКА ПО ПОЛИМОРФИЗМУ В ПОЗИЦИИ 2579 ГЕНА BRCA1 (rs4986850)

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4876399A (en) 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
US4942184A (en) 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5278324A (en) 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US5710287A (en) 1991-09-23 1998-01-20 Florida State University Taxanes having an amino substituted side-chain and pharmaceutical compositions containing them
CA2130578A1 (en) 1992-04-17 1993-10-28 Geewananda P. Gunawardana Taxol derivatives
CZ292993B6 (cs) 1992-12-23 2004-01-14 Bristol-Myers Squibb Company Způsob přípravy taxanu nesoucího oxazolinový postranní řetězec a taxan tímto způsobem připravený
US5840929A (en) 1995-04-14 1998-11-24 Bristol-Myers Squibb Company C4 methoxy ether derivatives of paclitaxel
US5773629A (en) 1996-06-14 1998-06-30 Industrial Technology Research Institute Synthesis of (4S, 5R) -2, 4-diphenyl-5-carboxy-oxazoline derivative as taxol side-chain precursor
US5773464A (en) 1996-09-30 1998-06-30 Bristol-Myers Squibb Company C-10 epoxy taxanes
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
US5902822A (en) 1997-02-28 1999-05-11 Bristol-Myers Squibb Company 7-methylthiooxomethyl and 7-methylthiodioxomethyl paclitaxels
US6017935A (en) 1997-04-24 2000-01-25 Bristol-Myers Squibb Company 7-sulfur substituted paclitaxels
HUP0101457A3 (en) 1997-12-31 2003-01-28 Bristol Myers Squibb Co Antitumor 2-aroyl-4-acyl paclitaxel analogs and medicaments containing them , their intermediates and method for producing them
KR100634249B1 (ko) 1999-08-11 2006-10-17 브리스톨-마이어스스퀴브컴파니 파클리탁셀 ｃ-4 메틸 카르보네이트 동족체의 제조 방법
PL185957B1 (pl) 1999-10-08 2003-09-30 Tomasz Byrski Sposób i zestaw diagnostyczny do wykrywania mutacji genów BRCA1 i BRCA2 w polskich rodzinach z agregacją raków sutka i/lub jajnika
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
US6916942B2 (en) 2000-02-03 2005-07-12 Bristol-Myers Squibb Company Process for the preparation of C-4 carbonate taxanes
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
GB0226595D0 (en) * 2002-11-15 2002-12-24 Univ Belfast Cancer therapy determination
PL209997B1 (pl) 2004-01-15 2011-11-30 Tomasz Byrski Sposób i zestaw do wykrywania wysokiej genetycznie uwarunkowanej predyspozycji do raka sutka i/lub jajnika u osoby pochodzenia polskiego oraz zastosowanie wybranych mutacji w obrębie genu BRCA1
US7563570B2 (en) * 2004-10-29 2009-07-21 Pangaea Biotech Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression

Also Published As

Publication number Publication date
EP2032720A2 (en) 2009-03-11
WO2007139411A2 (en) 2007-12-06
CA2650448A1 (en) 2007-12-06
US20080241834A1 (en) 2008-10-02
ZA200810173B (en) 2009-11-25
WO2007139411A3 (en) 2008-07-17
AU2007268378A1 (en) 2007-12-06
EP2032720B1 (en) 2014-05-21
PL217731B1 (pl) 2014-08-29
RU2008146886A (ru) 2010-07-20

Similar Documents

Publication Publication Date Title
IL233764A0 (en) Interpreting systems of geological deposits
GB2454359B (en) Seismic sensing
GB2453269B (en) Remote logging operations environment
GB2442975B (en) Seismic explosive system
EP2088965A4 (en) SEGMENTED RING PLACEMENT
GB2443843B (en) Seafloor-following streamer
GB0621625D0 (en) Location detection
ZA200806154B (en) Gastric ring
PL397850A1 (pl) Układ szczelinowania w odwiercie
GB0619243D0 (en) Activation sensing
GB0813307D0 (en) Retro-reflector
PL379827A1 (pl) Wykrywanie obniżonej odpowiedzi na chemioterapię z zastosowaniem cytostatyków z grupy taksoidów
GB2453317B (en) Retaining a proppant by use of an organosilane
PL2234987T3 (pl) Pochodne perhydrochinoksaliny jako leki przeciwbólowe
GB0613737D0 (en) Retroreflector
GB0621990D0 (en) Detection
EP2208082B8 (de) Ortungsbake
GB2445358B (en) Hole depth sensing
GB0603095D0 (en) Leak detection
GB2444374B (en) Seismic sensor
GB0625483D0 (en) An annular regenerator assembly
GB0600632D0 (en) Vest with sensors
AU2006904205A0 (en) Retaining ring
GB0614326D0 (en) Lizard brick bag protector
GB0604101D0 (en) Underground passage resevior